An antigen-binding protein, or an antigen-binding fragment thereof that binds to a Lewis X type glycan on SLAMF7, comprising (1) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GYTFTSYWIH; a VHCDR2 having the amino acid sequence EINPSNGRTNFNEKFKN and a VHCDR3 having the amino acid sequence VDYDEAY; and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence RSSKSLLHSNGITYLY, a VLCDR2 having the amino acid sequence QMSNLAS, and a VLCDR3 having the amino acid sequence AQNLELWT is provided. Methods of using the antibody for detecting or treating cancer, and a kit comprising the antibody are also provided.

Embodiments in accordance with the present disclosure include apparatuses, devices, and methods. An example method is directed to detecting cancer stem cells (CSCs) in a biological sample of a subject. The method includes causing a physical interaction between the biological sample and an antibody by exposing the biological sample to the antibody and determining a presence of CSCs in the biological sample by detecting binding between the antibody and a glycan biomarker. The glycan biomarker includes at least one chain selected from the group consisting of polylactosamine chains, oligosaccharide chains, and combinations thereof, the at least one chain having branches selected from the group consisting of II (Gal1,4GlcNAc1,6), II/I (Gal 1,3GlcNAc 1,6), II/I (Gal 1 4/3GlcNAc 1,6)-moieties, and combinations thereof.

The invention relates to a method for establishing an index for a given cancer grade. The method includes profiling glycan distribution pattern of a reference cancer cell sample; adsorbing the profiled reference cancer cell sample with adsorbents; measuring the amount of the adsorbents adhering onto the profiled reference cancer cell sample; and acquiring reference correlations between the glycan distribution pattern of the reference cancer cell sample and the amount of the adsorbents adhering onto the profiled reference cancer cell sample to form the index of the given cancer grade. An index for a given cancer grade and a method for grading cancer of a test cell sample are also provided.

Lung cancer can be detected by measuring sites in pancreatic ribonuclease 1 (also abbreviated as RNase 1), wherein each of the sites is a site capable of being modified with an N-linked sugar chain. Lung cancer is detected by measuring items A and B as mentioned below and then comparing the ratio of the value of A to the value of B: A=the amount of sites in pancreatic ribonuclease 1, wherein the sites are sites each capable of being modified with an N-linked sugar chain and each having an N-linked sugar chain bound thereto or each having an N-linked sugar chain unbound thereto; and B=the amount of sites in pancreatic ribonuclease 1, wherein the sites are sites each capable of being modified with an N-linked sugar chain.

Disclosed is an antibody, functional fragment, and derivative thereof, which binds specifically to the OAcGD2 ganglioside, the antibody including i) a humanized light chain variable region (VL) polypeptide having the amino acid sequence SEQ id no 112; and ii) a humanized heavy chain variable region (VH) having the amino acid sequence SEQ id no 76; and its use in diagnostics and therapy.

The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.

The present disclosure relates to compositions, kits and methods for preparing and/or analysing biological samples from a subject. These compositions, kits and methods may be useful in applications, such as diagnosing cancer and/or or determining a prognosis therefor.

Disclosed are biomarkers for Barrett's esophagus and esophageal adenocarcinoma, and uses thereof, such as in methods for detecting the presence, and monitoring progression, of Barrett's esophagus and esophageal adenocarcinoma. Also disclosed are methods for treating and methods of monitoring the treatment of Barrett's esophagus and esophageal adenocarcinoma, as well as kits and compositions for use in such methods.

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.